Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARQT
SELLArcutis Biotherapeutics, Inc. · Healthcare · United States · $3.4B · Avg Vol: $47M/d
COMPANY DESCRIPTION
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for immune-mediated dermatological diseases, with its lead product, Zoryve, for plaque psoriasis. Its competitive moat is a proprietary drug development platform targeting specific disease pathways in dermatology, offering novel therapeutic options with strong intellectual property. Arcutis is a specialized biopharma company focused on dermatological innovation, transitioning to a commercial-stage entity with an approved product and robust pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7M | 59.6M | 196.5M | 376.1M | 367.3% | 415.6M | 500.1M | 647.2M | 31.2% |
| EPS | -2.76 | -3.78 | -1.16 | -0.13 | — | -0.02 | — | — | — |
| Shares | 125.1M | 96.8M | 117.8M | 123.3M | -1.4% | 125.1M | — | — | — |
| Debt | 202.5M | 205.9M | 109.8M | 114.2M | -17.4% | 114.7M | — | — | — |
| Equity | 209.6M | 88.7M | 157.5M | 189.5M | -3.3% | — | — | — | — |
| Op CF | -257.7M | -247.1M | -112.2M | -5.6M | — | 27.0M | — | — | — |
| Inv CF | -87.2M | 180.2M | 28.8M | -30.3M | — | — | — | — | — |
| Fin CF | 301.8M | 101.3M | 66.2M | 7.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARQT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc.(you) | $3.4B | 30 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
| RLAY | Relay Therapeutics, Inc. | $4.0B | 31 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
| EWTX | Edgewise Therapeutics, Inc. | $4.4B | 30 | SELL |
| TNGX | Tango Therapeutics, Inc. | $4.3B | 29 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 29 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%